Voya Investment Management LLC Lowers Stake in LivaNova PLC $LIVN

Voya Investment Management LLC lowered its stake in shares of LivaNova PLC (NASDAQ:LIVN) by 17.6% in the third quarter, Holdings Channel reports. The institutional investor owned 99,254 shares of the company’s stock after selling 21,244 shares during the period. Voya Investment Management LLC’s holdings in LivaNova were worth $5,199,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Invesco Ltd. raised its position in shares of LivaNova by 714.7% in the 2nd quarter. Invesco Ltd. now owns 1,028,713 shares of the company’s stock worth $46,313,000 after acquiring an additional 902,447 shares in the last quarter. AQR Capital Management LLC raised its holdings in LivaNova by 111.7% in the first quarter. AQR Capital Management LLC now owns 1,571,295 shares of the company’s stock worth $60,809,000 after purchasing an additional 829,115 shares in the last quarter. Scopia Capital Management LP bought a new position in LivaNova in the second quarter worth about $36,657,000. Artisan Partners Limited Partnership lifted its position in shares of LivaNova by 112.9% during the second quarter. Artisan Partners Limited Partnership now owns 1,247,609 shares of the company’s stock valued at $56,167,000 after buying an additional 661,480 shares during the last quarter. Finally, M&G PLC bought a new stake in shares of LivaNova in the 2nd quarter valued at about $11,762,000. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

LivaNova Stock Down 0.2%

LIVN stock opened at $63.13 on Friday. The company has a market capitalization of $3.45 billion, a P/E ratio of -15.78 and a beta of 1.02. LivaNova PLC has a 12 month low of $32.48 and a 12 month high of $65.57. The firm’s fifty day simple moving average is $58.12 and its 200-day simple moving average is $52.72. The company has a debt-to-equity ratio of 0.30, a current ratio of 1.33 and a quick ratio of 1.12.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the stock. Weiss Ratings reiterated a “sell (d+)” rating on shares of LivaNova in a research note on Monday. Wall Street Zen raised shares of LivaNova from a “buy” rating to a “strong-buy” rating in a report on Saturday, December 20th. The Goldman Sachs Group set a $55.00 price objective on LivaNova and gave the company a “neutral” rating in a report on Wednesday, October 1st. Needham & Company LLC reissued a “buy” rating and issued a $64.00 price objective on shares of LivaNova in a research report on Wednesday, September 3rd. Finally, Robert W. Baird set a $75.00 target price on LivaNova in a research note on Tuesday, December 16th. Six equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, LivaNova presently has a consensus rating of “Moderate Buy” and an average price target of $65.63.

LivaNova Company Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.